Literature DB >> 19265139

Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.

Aline Martayan1, Leonardo Sibilio, Elisa Tremante, Elisa Lo Monaco, Arend Mulder, Doriana Fruci, Agata Cova, Licia Rivoltini, Patrizio Giacomini.   

Abstract

To present virus and tumor Ags, HLA class I molecules undergo a complex multistep assembly involving discrete but transient folding intermediates. The most extensive folding abnormalities occur in cells lacking the class I L chain subunit, called beta(2)-microglobulin (beta(2)m). Herein, this issue was investigated taking advantage of eight conformational murine mAbs (including the prototypic W6/32 mAb) to mapped H chain epitopes of class I molecules, four human mAbs to class I alloantigens, as well as radioimmunoprecipitation, in vitro assembly, pulse-chase, flow cytometry, and peptide-pulse/ELISPOT experiments. We show that endogenous (HLA-A1, -A66, and -B58) as well as transfected (HLA-A2) heavy chains in beta(2)m-defective Burkitt lymphoma Daudi cells are capable of being expressed on the cell surface, although at low levels, and exclusively as immature glycoforms. In addition, HLA-A2 is: 1) partially folded at crucial interfaces with beta(2)m, peptide Ag, and CD8; 2) receptive to exogenous peptide; and 3) capable of presenting exogenous peptide epitopes (from virus and tumor Ags) to cytotoxic T lymphocytes (bulk populations as well as clones) educated in a beta(2)m-positive environment. These experiments demonstrate a precursor-product relationship between novel HLA class I folding intermediates, and define a stepwise mechanism whereby distinct interfaces of the class I H chain undergo successive, ligand-induced folding adjustments in vitro as well as in vivo. Due to this unprecedented class I plasticity, Daudi is the first human cell line in which folding and function of class I HLA molecules are observed in the absence of beta(2)m. These findings bear potential implications for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265139     DOI: 10.4049/jimmunol.0802316

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

2.  Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.

Authors:  A B Del Campo; J Carretero; J A Muñoz; S Zinchenko; F Ruiz-Cabello; G González-Aseguinolaza; F Garrido; N Aptsiauri
Journal:  Cancer Gene Ther       Date:  2014-06-27       Impact factor: 5.987

3.  Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers.

Authors:  Mepur H Ravindranath; Vadim Jucaud; Soldano Ferrone
Journal:  J Immunol Methods       Date:  2017-08-04       Impact factor: 2.303

4.  The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09.

Authors:  Alberto Cauli; Jacqueline Shaw; Joanna Giles; Hiroko Hatano; Oliwia Rysnik; Sravan Payeli; Kirsty McHugh; Grazia Dessole; Giovanni Porru; Elisabetta Desogus; Sarah Fiedler; Soraya Hölper; Amanda Carette; Miguel Angel Blanco-Gelaz; Alessandra Vacca; Matteo Piga; Valentina Ibba; Pietro Garau; Giorgio La Nasa; Carlos López-Larrea; Alessandro Mathieu; Christoph Renner; Paul Bowness; Simon Kollnberger
Journal:  Rheumatology (Oxford)       Date:  2013-06-26       Impact factor: 7.580

5.  Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies.

Authors:  Craig J Taylor; Vasilis Kosmoliaptsis; Jessie Martin; Graham Knighton; Dermot Mallon; J Andrew Bradley; Sarah Peacock
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

6.  Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Hongyan Li; Guozhu Shao; Yajing Zhang; Xiaomin Chen; Chengcheng Du; Kun Wang; Zairong Gao
Journal:  Cancer Imaging       Date:  2021-01-08       Impact factor: 3.909

7.  Targeting loss of heterozygosity for cancer-specific immunotherapy.

Authors:  Michael S Hwang; Brian J Mog; Jacqueline Douglass; Alexander H Pearlman; Emily Han-Chung Hsiue; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Drew M Pardoll; Sandra B Gabelli; Chetan Bettegowda; Nickolas Papadopoulos; Bert Vogelstein; Shibin Zhou; Kenneth W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

8.  KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis.

Authors:  Isabel Wong-Baeza; Anna Ridley; Jackie Shaw; Hiroko Hatano; Oliwia Rysnik; Kirsty McHugh; Christopher Piper; Simon Brackenbridge; Ricardo Fernandes; Anthoni Chan; Paul Bowness; Simon Kollnberger
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

Review 9.  Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells.

Authors:  Sebastian Montealegre; Peter M van Endert
Journal:  Front Immunol       Date:  2019-01-07       Impact factor: 7.561

10.  Adenosine-Induced NLRP11 in B Lymphoblasts Suppresses Human CD4+ T Helper Cell Responses.

Authors:  Irem Ozel; Ilgin Akkaya; Ece Oylumlu; Goksu Uzel; Ceren Ciraci
Journal:  J Immunol Res       Date:  2020-08-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.